Eli Lilly, Pfizer, Merck among Big Pharma losers in China's latest round of procurement bidding
The Pharma Data
AUGUST 20, 2020
Companies such as AstraZeneca, Sanofi and Eli Lilly have managed to keep business under the aggressive procurement program, but they had to live with major discounts. . It’s not a completely unforeseen shift, though. Pfizer’s established drugs business started showing a decline in China back in April 2019.
Let's personalize your content